Urologists in the UK are encouraged to follow the National Institute for Health and Care Excellence (NICE) guidelines for patient management. In 2014, members of the British Association of Urological Surgeons (BAUS) were asked in a survey what diagnostic pathway they would follow for themselves or their relatives if they had a raised prostate-specific antigen (PSA). It was found that only a quarter would follow NICE guidance. The current recommendations rely on pathological assessment of prostate tissue obtained at a transrectal ultrasound guided biopsy. Increasing evidence indicates that pre-biopsy multiparametric magnetic resonance imaging (mp-MRI) coupled with targeted biopsy approaches outperform random biopsies in the detection of clinically significant disease. Herein we discuss the role of magnetic resonance imaging and targeted biopsy approaches to diagnose prostate cancer in the modern era.
ThompsonIMGoodmanPJTangenCM. The influence of finasteride on the development of prostate cancer. N Engl J Med2003; 349: 215–224.
5.
BangmaCHRoemelingSSchroderFH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol2007; 25: 3–9.
6.
DjavanBRaveryVZlottaA. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop?J Urol2001; 166: 1679–1683.
7.
ScattoniVZlottaAMontironiR. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: A critical analysis of the literature. Eur Urol2007; 52: 1309–1322.
8.
BottSRYoungMPKellettMJ. and contributors to the UCLHTRPD. Anterior prostate cancer: Is it more difficult to diagnose?BJU Int2002; 89: 886–889.
9.
KomaiYNumaoNYoshidaS. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy. J Urol2013; 190: 867–873.
10.
WagenlehnerFMvan OostrumETenkeP. Infective complications after prostate biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol2013; 63: 521–527.
11.
BottSRHendersonAMcLartyE. A brachytherapy template approach to standardize saturation prostatic biopsy. BJU Int2004; 93: 629–630.
12.
BottSRHendersonAHallsJE. Extensive transperineal template biopsies of prostate: Modified technique and results. Urology2006; 68: 1037–1041.
13.
TairaAVMerrickGSGalbreathRW. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis2010; 13: 71–77.
14.
StreeterEHBrewsterSF and BAUS Section of Oncology. NICE guidelines on prostate cancer active surveillance: Is UK practice leading the world?BJU Int2015; 115: 12–13.
15.
BarzellWEMelamedMR. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology2007; 70: 27–35.
16.
OnikGBarzellW. Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol2008; 26: 506–510.
17.
CrawfordEDWilsonSSTorkkoKC. Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int2005; 96: 999–1004.
18.
FurunoTDemuraTKanetaT. Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate2004; 58: 76–81.
19.
VyasLAcherPKinsellaJ. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: A single centre experience of 634 cases. BJU Int2014; 114: 32–37.
20.
AyresBEMontgomeryBSBarberNJ. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU Int2012; 109: 1170–1176.
21.
Dall’EraMAAlbertsenPCBangmaC. Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol2012; 62: 976–983.
22.
KlotzLVespriniDSethukavalanP. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol2015; 33: 272–277.
23.
BuskirkSJPinkstaffDMPetrouSP. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol Biol Phys2004; 59: 1360–1366.
24.
MerrickGSTaubenslagWAndreiniH. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int2008; 101: 1524–1529.
25.
MillerJPerumallaCHeapG. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg2005; 75: 48–50.
26.
DickinsonLAhmedHUAllenC. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: Recommendations from a European consensus meeting. Eur Urol2011; 59: 477–494.
27.
PuechPPotironELemaitreL. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology2009; 74: 1094–1099.
28.
LeeDJAhmedHUMooreCM. Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: Current applications and strategies. Curr Urol Rep2014; 15: 390.
29.
TanimotoANakashimaJKohnoH. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging2007; 25: 146–152.
30.
Rais-BahramiSSiddiquiMMVourgantiS. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int2015; 115: 381–388.
31.
RadtkeJPBoxlerSKuruTH. Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance. Prostate Cancer Prostatic Dis2015; 18: 288–296.
32.
SchimmollerLQuentinMArsovC. MR-sequences for prostate cancer diagnostics: Validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol2014; 24: 2582–2589.
HamoenEHde RooijMWitjesJA. Use of the prostate imaging reporting and data system (pi-rads) for prostate cancer detection with multiparametric magnetic resonance imaging: A diagnostic meta-analysis. Eur Urol2015; 67: 1112–1121.
35.
GreyADChanaMSPopertR. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting. BJU Int2015; 115: 728–735.
36.
BarentszJOWeinrebJCVermaS. Synopsis of the PI-RADS v2 Guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use. Eur Urol2016; 69: 41–49.
BacoERudEEriLM. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy. Eur Urol2016; 69: 149–156.
39.
DelongchampsNBLefevreABouazzaN. Detection of significant prostate cancer with magnetic resonance targeted biopsies–should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?J Urol2015; 193: 1198–1204.
40.
HongCWRais-BahramiSWalton-DiazA. Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsies obtained from axial and sagittal approaches. BJU Int2015; 115: 772–779.
41.
GayetMvan der AaABeerlageHP. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: A systematic review. BJU Int2016; 117: 392–400.
42.
ValerioMDonaldsonIEmbertonM. Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: A systematic review. Eur Urol2015; 68: 8–19.
43.
KasivisvanathanVDufourRMooreCM. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol2013; 189: 860–866.
44.
ArsovCRabenaltRBlondinD. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol2015; 68: 713–720.
45.
BacoEUkimuraORudE. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: Correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol2015; 67: 787–794.
46.
SiddiquiMMRais-BahramiSTurkbeyB. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA2015; 313: 390–397.
47.
MozerPRoupretMLe CossecC. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. BJU Int2015; 115: 50–57.
48.
PokornyMRde RooijMDuncanE. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol2014; 66: 22–29.
49.
ThompsonJEMosesDShnierR. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: A prospective study. J Urol2014; 192: 67–74.
50.
Abd-AlazeezMKirkhamAAhmedHU. Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: A paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis2014; 17: 40–46.
51.
WysockJSRosenkrantzABHuangWC. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: The PROFUS trial. Eur Urol2014; 66: 343–351.
52.
Rais-BahramiSSiddiquiMMTurkbeyB. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol2013; 190: 1721–1727.
53.
DelongchampsNBPeyromaureMSchullA. Prebiopsy magnetic resonance imaging and prostate cancer detection: Comparison of random and targeted biopsies. J Urol2013; 189: 493–499.
54.
KuruTHRoethkeMCSeidenaderJ. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol2013; 190: 1380–1386.
55.
PuechPRouviereORenard-PennaR. Prostate cancer diagnosis: Multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy–prospective multicenter study. Radiology2013; 268: 461–469.
56.
LoganJKRais-BahramiSTurkbeyB. Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int2014; 114: 641–652.
57.
MarksLYoungSNatarajanS. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol2013; 23: 43–50.
58.
MooreCMKasivisvanathanVEggenerS. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an International Working Group. Eur Urol2013; 64: 544–552.
59.
HambrockTHoeksCHulsbergen-van de KaaC. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol2012; 61: 177–184.
60.
PuechPOuzzaneAGaillardV. Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. Biomed Res Int2014; 2014: 819360.
61.
ValerioMMcCartanNFreemanA. Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. Urol Oncol2015; 33: 424e9–e16.
62.
MouravievVVermaSKalyanaramanB. The feasibility of multiparametric magnetic resonance imaging for targeted biopsy using novel navigation systems to detect early stage prostate cancer: The preliminary experience. J Endourol2013; 27: 820–825.
63.
StamatakisLSiddiquiMMNixJW. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer2013; 119: 3359–3366.
64.
PintoPAChungPHRastinehadAR. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol2011; 186: 1281–1285.
65.
SiddiquiMMRais-BahramiSTruongH. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol2013; 64: 713–719.
66.
NatarajanSMarksLSMargolisDJ. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol2011; 29: 334–342.
67.
SonnGANatarajanSMargolisDJ. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol2013; 189: 86–91.
68.
RudEBacoEEggesboHB. MRI and ultrasound-guided prostate biopsy using soft image fusion. Anticancer Res2012; 32: 3383–3389.
69.
FiardGHohnNDescotesJL. Targeted MRI-guided prostate biopsies for the detection of prostate cancer: Initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance/transrectal ultrasound image fusion. Urology2013; 81: 1372–1378.
70.
MiyagawaTIshikawaSKimuraT. Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol2010; 17: 855–860.
71.
BottSRLangleySE. Prostate biopsy: It’s not NICE for UK urologists. ePoster P111. BJU Int2015; 115: 60.
MowattGScotlandGBoachieC. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: A systematic review and economic evaluation. Health Technol Assess2013; 17: vii-xix, 1–281.
74.
De RooijMCrienenSWitjesJA. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: A modelling study from a health care perspective. Eur Urol2014; 66: 430–436.
